Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). (Q41719274)

8 October 2017

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). (English)

1 reference

8 October 2017

phase II clinical trial

0 references

1 reference

Virginia G Kaklamani

1

1 reference

8 October 2017

Jacqueline S Jeruss

2

1 reference

8 October 2017

Elisha Hughes

3

1 reference

8 October 2017

Kalliopi Siziopikou

4

1 reference

8 October 2017

Kirsten M Timms

5

1 reference

8 October 2017

Alexander Gutin

6

1 reference

8 October 2017

Victor Abkevich

7

1 reference

8 October 2017

Zaina Sangale

8

1 reference

8 October 2017

Cara Solimeno

9

1 reference

8 October 2017

Krystal L Brown

10

1 reference

8 October 2017

Joshua Jones

11

1 reference

8 October 2017

Anne-Renee Hartman

12

1 reference

8 October 2017

Caitlin Meservey

13

1 reference

8 October 2017

Borko Jovanovic

14

1 reference

8 October 2017

Irene Helenowski

15

1 reference

8 October 2017

Seema A Khan

16

1 reference

8 October 2017

Kevin Bethke

17

1 reference

8 October 2017

Nora Hansen

18

1 reference

8 October 2017

Regina Uthe

19

1 reference

8 October 2017

Sara Giordano

20

1 reference

8 October 2017

Steven Rosen

21

1 reference

8 October 2017

Kent Hoskins

22

1 reference

8 October 2017

Jamie Von Roenn

23

1 reference

8 October 2017

Sarika Jain

24

1 reference

8 October 2017

Vamsi Parini

25

1 reference

8 October 2017

William Gradishar

26

1 reference

8 October 2017

language of work or name

English

0 references

publication date

26 May 2015

1 reference

Breast Cancer Research and Treatment

8 October 2017

1 reference

8 October 2017

151

1 reference

8 October 2017

629-638

1 reference

8 October 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-015-3435-y

8 October 2017

0 references

cites work

Triple negative tumours: a critical review

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Mechanisms of TGF-beta signaling from cell membrane to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Cancer susceptibility and the functions of BRCA1 and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Phospho-specific Smad3 signaling: impact on breast oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Cyclin E and survival in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Examining the role of cyclin D1 in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Aging is not programmed: genetic pseudo-program is a shadow of developmental growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Pin1 promotes transforming growth factor-beta-induced migration and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3435-Y

10.1007/S10549-015-3435-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

0 references

1 reference